Literature DB >> 22735941

IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population.

Yan Xu1, Yao Liu, Shandong Pan, Li Liu, Jibin Liu, Xiangjun Zhai, Hongbing Shen, Zhibin Hu.   

Abstract

BACKGROUND: The interleukin-23 receptor (IL-23R) plays an important role in the T-helper 17 cell-mediated inflammatory process and is also involved in tumor immune surveillance, which may be linked to carcinogenesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). In this study, we hypothesized that potentially functional genetic variants of the IL-23R gene may modify HCC risk.
METHODS: We genotyped two single-nucleotide polymorphisms (SNPs) of IL-23R, rs6682925 and rs1884444, in a case-control study of 837 HCC cases, 899 HBV surface antigen (HBsAg)-positive controls, and 743 HBsAg-negative controls. A reporter gene assay was performed to evaluate the functional relevance of the rs6682925 SNP located at the promoter region of the IL-23R gene.
RESULTS: We found that the two SNPs were associated with the risk of HCC when compared with both the HBsAg-positive and -negative controls. When compared with all controls, IL-23R rs6682925 and rs1884444 both increased the HCC risk in a recessive genetic model [rs6682925 CC vs. TT/TC: odds ratio (OR) 1.35, 95 % confidence interval (CI) 1.07-1.70; rs1884444 GG vs. TT/TG: OR 1.36, 95 % CI 1.05-1.77]. Furthermore, the variant C allele of rs6682925 in the promoter region of IL-23R was associated with increased reporter gene activity.
CONCLUSIONS: These findings indicate that genetic variants in IL-23R may contribute to HCC development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735941     DOI: 10.1007/s00535-012-0620-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  37 in total

1.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma.

Authors:  C J Chen; L Y Wang; S N Lu; M H Wu; S L You; Y J Zhang; L W Wang; R M Santella
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

4.  Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

Authors:  M Barajas; G Mazzolini; G Genové; R Bilbao; I Narvaiza; V Schmitz; B Sangro; I Melero; C Qian; J Prieto
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

5.  Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma.

Authors:  H Kuper; A Tzonou; E Kaklamani; C C Hsieh; P Lagiou; H O Adami; D Trichopoulos; S O Stuver
Journal:  Int J Cancer       Date:  2000-02-15       Impact factor: 7.396

6.  Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells.

Authors:  Yan-Qing Wang; Shin-Ichi Ugai; Osamu Shimozato; Ling Yu; Kiyoko Kawamura; Hiroshi Yamamoto; Taketo Yamaguchi; Hiromitsu Saisho; Masatoshi Tagawa
Journal:  Int J Cancer       Date:  2003-07-20       Impact factor: 7.396

Review 7.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

8.  The prevalence of Th17 cells in patients with gastric cancer.

Authors:  Bin Zhang; Guanghua Rong; Huafeng Wei; Meng Zhang; Jianwei Bi; Liye Ma; Xuchao Xue; Guo Wei; Xiaokang Liu; Guoen Fang
Journal:  Biochem Biophys Res Commun       Date:  2008-07-23       Impact factor: 3.575

Review 9.  [Roles of hepatitis B virus and hepatitis C virus in hepato-carcinogenesis].

Authors:  Zhong-zheng Zhu; Wen-ming Cong
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-09

10.  GATA transcription factors as potentiators of gut endoderm differentiation.

Authors:  P Bossard; K S Zaret
Journal:  Development       Date:  1998-12       Impact factor: 6.868

View more
  12 in total

Review 1.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in Alcoholic Liver Disease.

Authors:  Hsiao-Yen Ma; Jun Xu; Xiao Liu; Yunheng Zhu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; Dilip V Jeste; Igor Grant; Amanda J Roberts; Candice Contet; Cedric Geoffroy; Binhai Zheng; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2016-02-19

3.  Functional polymorphisms in interleukin-23 receptor and susceptibility to coronary artery disease.

Authors:  Meiyan Zhang; Zhen-Rong Cai; Bili Zhang; Xinmeng Cai; Wei Li; Zhifu Guo; Lan Ma
Journal:  DNA Cell Biol       Date:  2014-12       Impact factor: 3.311

4.  Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection.

Authors:  Anuradha Bandaru; Kamakshi P Devalraju; Padmaja Paidipally; Rohan Dhiman; Sambasivan Venkatasubramanian; Peter F Barnes; Ramakrishna Vankayalapati; Vijayalakshmi Valluri
Journal:  Eur J Immunol       Date:  2014-04-23       Impact factor: 5.532

5.  IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

Authors:  Anne-Marie Baird; Eilis Dockry; Anne Daly; Emma Stack; Derek G Doherty; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Oncol       Date:  2013-06-19       Impact factor: 6.244

6.  Systematic Review and Meta-Analysis on the Association between Polymorphisms in Genes of IL-12 Signaling Pathway and Hepatocellular Carcinoma Risk.

Authors:  Yao Xiao; Guodong Liu; Liansheng Gong
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

Review 7.  Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?

Authors:  Elizabeth N Ergen; Nabiha Yusuf
Journal:  Exp Dermatol       Date:  2018-07       Impact factor: 3.960

8.  Potentially functional polymorphism in IL-23 receptor and risk of acute myeloid leukemia in a Chinese population.

Authors:  Xifeng Qian; Songyu Cao; Guohua Yang; Yun Pan; Chenyu Yin; Xiang Chen; Ying Zhu; Yun Zhuang; Yunfeng Shen; Zhibin Hu
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

9.  High expression of 23 kDa protein of augmenter of liver regeneration (ALR) in human hepatocellular carcinoma.

Authors:  Hai-Ying Yu; Man-Hua Zhu; Dai-Rong Xiang; Jun Li; Ji-Fang Sheng
Journal:  Onco Targets Ther       Date:  2014-06-02       Impact factor: 4.147

Review 10.  Association of IL-23R Polymorphisms (rs6682925, rs10889677, rs1884444) With Cancer Risk: A PRISMA-Compliant Meta-Analysis.

Authors:  Xing-Han Liu; Zhi-Ming Dai; Hua-Feng Kang; Shuai Lin; Xiao-Bin Ma; Meng Wang; Kang Liu; Cong Dai; Xi-Jing Wang; Zhi-Jun Dai
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.